Table 6 Cox proportional hazards model for our dataset. In each calculation number of samples is 115
n = 115 | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
Clinical data | Hazard ratio | 95% confidence interval | p-value | Hazard ratio | 95% confidence interval | p-value (p-value of model) |
Age (≥60) | 1.967 | 1.01–3.833 | 0.043 | 2.825 | 1.330–6.000 | 0.007 (8.737e-12) |
Gender (Male vs. Female) | 1.544 | 0.982–2.426 | 0.058 | |||
Metastasis presence | 6.900 | 3.392–14.04 | 8.982e-10 | 6.692 | 3.137–14.278 | 8.8e-07 (8.737e-12) |
Lymph node infiltration | 2.016 | 1.367–2.975 | 3.366e-4 | 2.234 | 1.352–3.691 | 0.002 (8.737e-12) |
Tumor size (T3/T4 vs. T1/T2) | 1.867 | 1.143–3.048 | 0.011 | |||
Location (rectum vs. colon) | 1.797 | 1.139–2.836 | 0.011 | 2.047 | 1.212–3.457 | 0.007 (8.737e-12) |
Late stage vs. early stage | 1.926 | 1.172–3.165 | 0.009 | |||
RT | 1.134 | 0.534–2.409 | 0.743 | |||
Chemotherapy | 1.148 | 0.653–2.018 | 0.632 | |||
Cancer progression | 2.573 | 1.583–4.184 | 8.385e-05 | |||
Methylation (methylated vs unmethylated) | ||||||
CEP55 | 1.276 | 0.312–5.217 | 0.734 | |||
FOXD3 | ND | |||||
FOXF2 | 1.335 | 0.579–3.077 | 0.500 | |||
GNAO1 | ND | |||||
GRIA4 | 0.339 | 0.106–1.092 | 0.05729 | |||
KCNA5 | 0.0704 | 0.009–0.572 | 0.001 | |||
Expression (upregulated vs down-regulated) | ||||||
CEP55 | ND | |||||
FOXD3 | 1.664 | 0.485–5.702 | 0.413 | |||
FOXF2 | 0.267 | 0.034–2.086 | 0.176 | |||
GNAO1 | 4.277 | 0.4992–36.65 | 0.148 | |||
GRIA4 | 4.478 | 0.4999–40.11 | 0.142 | |||
KCNA5 | 3.699 | 0.9577–14.29 | 0.042 | |||